Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM

NCT00977431 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00977431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00977431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
September 17, 2009
Completion date
September 12, 2017
Enrollment
36 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma